Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Decitabine with IAG for Relapsed/Refractory AML
NCT03985007Phase 2Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Remission Rate at 1 month and Overall Survival at 1 year. Started Jan 2018; status: completed.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03985007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985007.